VHL

Across TCGA pan-cancer cohorts, VHL mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VHL data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VHL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VHL expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where VHL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.228	0.611	.013	17	view →
HNSC	DFS	Median	All	0.770	0.527	.013	11	view →
LSCC	OS	Median	II,III,IV	0.825	0.922	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

VHL–PDAC (OS)

Open the PDAC breakdown →